Myosotis Investments B.V. is founded in 2024. It focuses on catalyzing advancements in life sciences, in particular molecular diagnostics by investing in companies that are reshaping healthcare. The firm’s portfolio includes 1) Antwerp, Belgium based company IDEVAX B.V., which is pioneering innovative intradermal delivery methods with its patented VAX-ID device to improve vaccine and therapeutic applications, 2 Welsh, UK based company Kairos Biotech Ltd., a developer of next-generation small-molecule immunotherapies aimed at enhancing transplant success and accessibility and 3) Tzu Cancer Therapeutics B.V. based on Amsterdam Science Park that was founded in July 2024 and who aims to develop personalized therapies based on the molecular analysis of Circulating Tumor Cells (CTCs).

Myosotis Investments is committed to supporting transformative technologies that address complex medical needs and drive long-term healthcare progress.